National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry by Bibalo, C et al.
POSTER PRESENTATION Open Access
National CAPS (Cryopyrin-Associated Periodic
Syndrome) Registry
C Bibalo
1*, G Paloni
1, L Lepore
1, M Gattorno
2, M Finetti
2, F Zulian
3, G Martini
3, M Alessio
4, M Cattalin
5, A Stabile
6,
D Rigante
6, A Insalaco
7, R Manna
8, R Gallizzi
9, L Obici
10, L Cantarini
11, S Martino
12, R Cionsolini
13
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Introduction
The aim of the present study was to evaluate the long
term follow-up of patients enrolled in the Italian Regis-
try of cryopirin associated periodic sindrome (CAPS).
Patients and methods
The Italian CAPS Registry started in 2004 and has cur-
rently enrolled 29 patients: 16 with Chronic Infantile
Neurologic Cutaneous Articular Syndrome (CINCAs), 8
with Muckles Welles syndrome (MWS) and 5 with
Familial Cold Urticaria (FCU). 16 patients were treated
with Anakinra (IL-1 receptor antagonist) at 1 mg/kg/
day. The Child Health Questionnaire (CHQ-PF 50) was
used to assess the health related quality of life.
Results
Rapid clinical and laboratory improvement was observed
in all patients, but six patients who declined treatment
and experienced progressive course of the disease. All
the treated patients maintained persistent remission; 5
patients required an increase of the dosage to 300 mg
per day. No adverse effects were recorded except injec-
tion site reactions.Until today, 8 of the 16 patients initi-
ally treated with Anakinra have subsequently switched
to Canakinumab (monoclonal human antiIL-1b anti-
body) at the initial dose of 150 mg every 8 weeks.
Conclusion
IL-1 inhibition seems to be crucial in modifying the nat-
ural history of CAPS. Long-term follow up of patients
treated with Anakinra established its efficacy and toler-
ability. The same evaluation will be done for Canakinu-
mab, that appears to be equally effective but whose side
effects still need to be evaluated. The bimonthly admin-
istration of Canakinumab may be certainly useful, espe-
cially in pediatric population, however its long half-life
implies a tight surveilance in case of infections.
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